Biosign licenses award-winning applepeak source code.

TORONTO, Nov. 18, 2013 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign" or the "Company") is pleased to announce the execution of a license agreement with Saint John NB based applepeak software to acquire a fully paid up, perpetual, royalty free, non-exclusive license to use and modify the source code for the "applepeak Wellness Record" software platform.

On April 26, 2012 applepeak's Wellness Record received a Silver Edison Award in the Lifestyle & Social Impact category. Being recognized with an Edison Award has become one of the highest accolades a company can receive in the name of innovation and business. The awards are named after Thomas Alva Edison (1847-1931) whose inventions, new product development methods and innovative achievements literally changed the world, garnered him 1,093 U.S. patents, and made him a household name.

The Wellness Record enables organizations to improve the outcomes of their health and wellness initiatives and yield positive returns through a combination of evidence based e-health content, online health risk assessments, informational resources, flexible e-learning technologies, health management tools, and professional oversight/support services. It's an innovative platform that gives individuals private, personalized online wellness resources to manage their health including interactive health tools, certified medical content, fitness and medical device integration, health trackers, goal-setting tools, clinical monitoring, and program-based social media.

Biosign will now integrate features from the Wellness Record into our next iteration of Healthanywhere™. The total license fee of $175,000 was satisfied with the issuance of 3.5 million common shares of Biosign at $0.05/share. The transaction is subject to board & TSX approval, and all securities issued are subject to a hold period of 4 months and 1 day, plus further agreed-upon restrictions on selling over a period of 24 months.

About Biosign Technologies Inc.
Biosign Technologies Inc. (TSXV: BIO) provides automated, software enabled health information solutions including the Pulsewave® Health Monitor and the Healthanywhere™ Patient monitoring / self-management platform. The Company's Pulsewave® Health Monitor solution enables pulse wave data collection for cardiovascular clinical decision support and self-care, while its Healthanywhere™ solution offers industry-leading remote patient monitoring and patient centred care management. The Company also offers a number of cardiovascular screening programs for consumers under its Heart Friendly™ brand, including Heart Friendly™ Practice, Heart Friendly™ Dentist, and Heart Friendly™ Fitness. For more information on Biosign, please visit www.biosign.com

About the Edison Awards
The Palos Park, IL based Edison Awards represent the spirit of innovation personified by Thomas Edison, inspiring the drive of global inventors to remain in the forefront of creativity and ingenuity. Sponsors of the 2012 Edison Awards included Nielsen, USA TODAY, Discovery Communications, SCIENCE, CSRware, and ViridiSTOR. For more information go to www.edisonawards.com

Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in the company's filings with Canadian securities regulators (www.sedar.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Biosign Technologies Inc.

For further information:

Biosign Contact Information:
Robert Kaul
Chief Executive Officer
Biosign Technologies
Phone: (416) 218-9800 ext. 201
Email: ceo@biosign.com